Welcome to our dedicated page for Aspira Womens Health SEC filings (Ticker: AWHL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aspira Women's Health Inc. filings document the public-company record for a women's health diagnostics business focused on noninvasive gynecologic disease testing. Recent Form 8-K reports cover executive appointments, laboratory-services agreements, secured borrowing, equity-purchase arrangements, investor-presentation disclosures, and other material events involving the company's common stock and operating relationships.
Proxy materials describe board matters, executive compensation, equity awards, and shareholder voting items. Registration statements and related agreements disclose securities offerings, resale registration matters, common stock terms, filer status, and capital-structure effects. The filing record also includes a Form 12b-25 notice related to timing of the annual report and accounting completion for Aspira's Form 10-K.
Aspira Women’s Health Inc. filed an amended Form 8-K to correct the form of its Amended and Restated Series A Common Stock Warrant. The company stated that the version previously included with its September 25, 2025 disclosure inadvertently listed an incorrect termination date. The corrected warrant form is filed as Exhibit 4.1 and incorporated by reference.
The amendment is reported under Item 1.01 (Entry into a Material Definitive Agreement), with Item 3.02 (Unregistered Sales of Equity Securities) incorporating Item 1.01 by reference. The earliest event date is September 19, 2025.
Aspira Women’s Health filed Amendment No. 1 to a Form S-1 to register the resale of up to 29,226,527 shares of common stock by selling stockholders. The registered shares comprise: 5,915,850 issued on conversion of senior secured convertible notes, 11,848,177 issuable upon exercise of Amended and Restated March 2025 Warrants, 6,550,000 issued under the September 2025 Purchase Agreement, and 4,912,500 issuable upon exercise of September 2025 Warrants.
The company is not selling any securities in this prospectus and will not receive proceeds from stockholder resales. If the Amended and Restated March 2025 Warrants or September 2025 Warrants are exercised for cash, Aspira estimates it would receive $7,831,237. Sales may occur from time to time using methods described under “Plan of Distribution.” Aspira’s common stock trades on the OTCQB as AWHL; the closing price was $0.52 on September 29, 2025. Shares outstanding were 42,655,918 as of September 29, 2025.
Aspira Women’s Health Inc. reported that on October 14, 2025 it upgraded its trading venue to OTCQX from the OTCQB Venture Market. The company now trades on OTCQX under the symbol AWHL.
Aspira Womens Health Inc. (AWHL) filed a registration statement to register up to 29,226,527 resale shares of its common stock held by selling stockholders. The resale pool comprises shares issued on conversion of convertible notes, shares underlying amended March 2025 warrants, shares issued under a September 2025 purchase agreement, and shares underlying September 2025 warrants. After giving effect to the offering the company expects 59,416,595 shares outstanding based on 42,655,918 shares outstanding as of September 29, 2025. The company will not receive proceeds from the resale by selling stockholders; however, it would receive the nominal cash exercise price if the listed warrants are exercised, estimated at $7,831,237. The prospectus highlights numerous risk factors including limited daily trading volume and concerns about the companys ability to continue as a going concern.
Aspira Women’s Health Inc. entered into an amendment to its March 2025 securities purchase agreement covering a prior $1,370,000 private placement of Senior Secured Convertible Promissory Notes, all of which have now converted into units of common stock and warrants. The amendment requires Aspira to file a Form S-1 registration statement by September 30, 2025 to register the common shares and the shares underlying the warrants issued in that financing.
The amendment also grants the participating purchasers, as a group, the right to appoint up to three directors to the board until the earlier of specified time and listing milestones or until their aggregate warrant holdings fall below fifty percent. In connection with this change, Aspira issued Amended and Restated Series A Common Stock Warrants, which now have a fixed exercise price of $0.35 per share, must be exercised for cash, have their term extended to six years from issuance, and begin to be exercisable six months after the issuance date.
Aspira Women's Health Inc. insider purchase and holdings update. Director Jack W. Schuler, as sole trustee of the Jack W. Schuler Living Trust, reported purchases and existing holdings in AWHL securities. On 09/17/2025 he purchased 1,111,111 shares of common stock at $0.45 per share and now beneficially owns 3,823,829 shares indirectly through the Living Trust. The filing also reports warrants totaling 2,661,422 underlying common shares across multiple strike prices and expirations, including an acquisition of 833,333 warrants exercisable at $0.75 (expiring 09/17/2030). A small disposition of 6,536 common shares and a prior disposal of 6,536 warrants at $2.25 are noted. The report is signed by Jack W. Schuler on 09/18/2025.
Aspira Women's Health Inc. insider purchase and holdings update. Director Jack W. Schuler, as sole trustee of the Jack W. Schuler Living Trust, reported purchases and existing holdings in AWHL securities. On 09/17/2025 he purchased 1,111,111 shares of common stock at $0.45 per share and now beneficially owns 3,823,829 shares indirectly through the Living Trust. The filing also reports warrants totaling 2,661,422 underlying common shares across multiple strike prices and expirations, including an acquisition of 833,333 warrants exercisable at $0.75 (expiring 09/17/2030). A small disposition of 6,536 common shares and a prior disposal of 6,536 warrants at $2.25 are noted. The report is signed by Jack W. Schuler on 09/18/2025.
Jeffrey K. Cohen, a director of Aspira Women's Health Inc. (AWHL), reported insider purchases on 09/17/2025. He acquired 55,556 shares of common stock at $0.45 per share and received 41,667 warrants exercisable immediately and expiring 09/17/2030, each warrant underlying one share. Following the reported transactions, the filing shows 375,697 shares beneficially owned indirectly (via HealthView Asset Management) and 60,913 shares indirectly by spouse.
Jeffrey K. Cohen, a director of Aspira Women's Health Inc. (AWHL), reported insider purchases on 09/17/2025. He acquired 55,556 shares of common stock at $0.45 per share and received 41,667 warrants exercisable immediately and expiring 09/17/2030, each warrant underlying one share. Following the reported transactions, the filing shows 375,697 shares beneficially owned indirectly (via HealthView Asset Management) and 60,913 shares indirectly by spouse.
Aspira Women's Health Inc. reporting persons Jack W. Schuler and the Jack W. Schuler Living Trust amended their Schedule 13D to disclose transactions that increase their ownership to 3,830,365 shares, representing 9.1% of the outstanding common stock based on a post-transaction share count of 42,205,918. The Trust purchased 1,111,111 shares and received a warrant to buy 833,333 shares under a September 2025 Purchase Agreement. The September 2025 Warrant is exercisable at $0.75 per share for five years. Mr. Schuler is sole trustee and the Trust holds shared voting and dispositive power over 3,823,829 shares.
Aspira Women's Health Inc. reporting persons Jack W. Schuler and the Jack W. Schuler Living Trust amended their Schedule 13D to disclose transactions that increase their ownership to 3,830,365 shares, representing 9.1% of the outstanding common stock based on a post-transaction share count of 42,205,918. The Trust purchased 1,111,111 shares and received a warrant to buy 833,333 shares under a September 2025 Purchase Agreement. The September 2025 Warrant is exercisable at $0.75 per share for five years. Mr. Schuler is sole trustee and the Trust holds shared voting and dispositive power over 3,823,829 shares.
Aspira Women's Health Inc. reporting persons Jack W. Schuler and the Jack W. Schuler Living Trust amended their Schedule 13D to disclose transactions that increase their ownership to 3,830,365 shares, representing 9.1% of the outstanding common stock based on a post-transaction share count of 42,205,918. The Trust purchased 1,111,111 shares and received a warrant to buy 833,333 shares under a September 2025 Purchase Agreement. The September 2025 Warrant is exercisable at $0.75 per share for five years. Mr. Schuler is sole trustee and the Trust holds shared voting and dispositive power over 3,823,829 shares.
Aspira Women's Health Inc. reporting persons Jack W. Schuler and the Jack W. Schuler Living Trust amended their Schedule 13D to disclose transactions that increase their ownership to 3,830,365 shares, representing 9.1% of the outstanding common stock based on a post-transaction share count of 42,205,918. The Trust purchased 1,111,111 shares and received a warrant to buy 833,333 shares under a September 2025 Purchase Agreement. The September 2025 Warrant is exercisable at $0.75 per share for five years. Mr. Schuler is sole trustee and the Trust holds shared voting and dispositive power over 3,823,829 shares.
John D. Fraser, a director of Aspira Women's Health Inc. (AWHL), reported purchases on 09/17/2025. He acquired 16,389 shares of common stock at $0.45 per share and purchased 12,292 warrants (exercise price $0.75, exercisable 09/17/2025, expiring 09/17/2030) covering 12,292 shares. After these transactions he reports beneficial ownership of 566,393 shares directly and 291,554 indirectly through Seamark Capital; 981,549 derivative securities are shown as owned.
John D. Fraser, a director of Aspira Women's Health Inc. (AWHL), reported purchases on 09/17/2025. He acquired 16,389 shares of common stock at $0.45 per share and purchased 12,292 warrants (exercise price $0.75, exercisable 09/17/2025, expiring 09/17/2030) covering 12,292 shares. After these transactions he reports beneficial ownership of 566,393 shares directly and 291,554 indirectly through Seamark Capital; 981,549 derivative securities are shown as owned.
Aspira Women's Health Inc. filed a Form D reporting a Regulation D offering under Rule 506(b). The company stated a $2,950,000 total offering size and reports $2,950,000 sold with $0 remaining, indicating the offering has been fully sold. The first sale date is listed as 2025-09-16. The securities offered include equity, options/warrants or other rights to acquire securities, and the securities issuable upon exercise of those rights. The filing lists 19 investors to date, indicates the offering will not last more than one year, and shows $0 in sales commissions and finders' fees. The company disclosed $0 of proceeds paid to named executive officers, directors or promoters. The Form D was signed by Michael Buhle, Chief Executive Officer, on 2025-09-18.
Aspira Women's Health Inc. filed a Form D reporting a Regulation D offering under Rule 506(b). The company stated a $2,950,000 total offering size and reports $2,950,000 sold with $0 remaining, indicating the offering has been fully sold. The first sale date is listed as 2025-09-16. The securities offered include equity, options/warrants or other rights to acquire securities, and the securities issuable upon exercise of those rights. The filing lists 19 investors to date, indicates the offering will not last more than one year, and shows $0 in sales commissions and finders' fees. The company disclosed $0 of proceeds paid to named executive officers, directors or promoters. The Form D was signed by Michael Buhle, Chief Executive Officer, on 2025-09-18.